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Introduction
The laboratory diagnosis of  active tuberculosis (TB) is only achieved in approximately 60% of  patients. 
This depends on microbiological identification of  Mycobacterium tuberculosis (Mtb), commonly under-
mined by the need to obtain poorly accessible samples from the site of  disease and by its poor sensitivity 
in extrapulmonary TB (1–4). The GeneXpert MTB/RIF PCR test for nucleic acid detection can give 
positive results within hours (5), but the fastest liquid culture systems detect bacteria in 10 to 19 days and 
require 6 weeks to obtain a definitively negative result, thereby delaying clinical decisions (6). Develop-
ment of  novel TB diagnostics is focused on rapid tests in easily obtained clinical samples (7). These aim 
to give better negative predictive value than current tests, particularly when clinical sampling of  the site 
of  disease is difficult and in high-transmission settings. They are also required to provide high positive 
BACKGROUND. Novel rapid diagnostics for active tuberculosis (TB) are required to overcome the 
time delays and inadequate sensitivity of current microbiological tests that are critically dependent 
on sampling the site of disease. Multiparametric blood transcriptomic signatures of TB have been 
described as potential diagnostic tests. We sought to identify the best transcript candidates as 
host biomarkers for active TB, extend the evaluation of their specificity by comparison with other 
infectious diseases, and to test their performance in both pulmonary and extrapulmonary TB.
METHODS. Support vector machine learning, combined with feature selection, was applied to 
new and previously published blood transcriptional profiles in order to identify the minimal 
TB‑specific transcriptional signature shared by multiple patient cohorts including pulmonary and 
extrapulmonary TB, and individuals with and without HIV‑1 coinfection.
RESULTS. We identified and validated elevated blood basic leucine zipper transcription factor 2 
(BATF2) transcript levels as a single sensitive biomarker that discriminated active pulmonary and 
extrapulmonary TB from healthy individuals, with receiver operating characteristic (ROC) area under 
the curve (AUC) scores of 0.93 to 0.99 in multiple cohorts of HIV‑1–negative individuals, and 0.85 
in HIV‑1–infected individuals. In addition, we identified and validated a potentially novel 4‑gene 
signature comprising CD177, haptoglobin, immunoglobin J chain, and galectin 10 that discriminated 
active pulmonary and extrapulmonary TB from other febrile infections, giving ROC AUCs of 0.94 to 1.
CONCLUSIONS. Elevated blood BATF2 transcript levels provide a sensitive biomarker that 
discriminates active TB from healthy individuals, and a potentially novel 4‑gene transcriptional 
signature differentiates between active TB and other infectious diseases in individuals presenting 
with fever.
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predictive value in regions of  low TB inci-
dence where alternative infections are more 
likely, and in immunocompromised patients 
who are at risk of  diverse infectious diseases.
Whole-blood transcriptomics has emerged 
ahead of  proteomics and metabolomics for 
diagnostic biomarker discovery in TB as a 
result of  well-established sample-processing 
pathways, and has led to development of  rapid 
sample-in-answer-out multiplex PCR plat-
forms (8). Numerous studies have described 
differential gene expression signatures in 
patients with active pulmonary TB compared 
with healthy uninfected individuals and those 
with latent TB infection (LTBI) (9–18). There 
has been comparatively little assessment of  
blood transcriptomes in extrapulmonary TB 
and limited evaluation of  the specificity of  TB-associated blood transcriptional signatures in comparison 
with other infectious or inflammatory diseases. The most recent studies have sought to reduce the number 
of  genes in a diagnostic signature, achieving as few as 3 or 4 genes to discriminate active TB from healthy 
individuals with or without LTBI, or to discriminate active TB from other diseases with variable accuracy 
(17, 18). In the present study, we sought to rank the genes that individually or in combination discrimi-
nated patients with active TB from all healthy individuals in diverse study cohorts including asymptomatic 
individuals with no prior TB exposure, those with LTBI, and those who have recovered from TB. We then 
proceeded to test the specificity of  peripheral blood gene expression signatures associated with active TB 
by comparison with a diverse repertoire of  other infectious diseases in patients presenting to hospital and 
extended our assessment of  these diagnostic transcriptional biomarkers to HIV-infected patients and those 
with extrapulmonary TB.
Results
Comparison of  blood transcriptomes in active TB and after long-term recovery. We first sought to identify the 
peripheral blood transcriptional signature of  active TB by comparison with subjects sampled from the 
same cohort after recovery, 2–4 years after completion of  TB treatment using samples obtained from 
the AdjuVIT study population comprising HIV-negative patients with smear- and culture-positive pul-
monary TB (Table 1) (19). This analysis revealed statistically significant and greater than 2-fold gene 
expression differences in 204 unique protein-coding transcripts (Figure 1A). Like other published data, 
active TB in this cohort was associated with increased expression of  genes associated with immune 
responses (Figure 1B), which showed some overlap with 2 other published blood transcriptional sig-
natures in adult patients with active pulmonary TB compared with either healthy volunteers (10) or 
subjects with LTBI (11) (Figure 1C). Consistent with previous studies (10), these transcripts showed 
significant enrichment for components of  IFN-associated pathways (Supplemental File 2; supplemental 
material available online with this article; doi:10.1172/jci.insight.87238DS1).
Application of  support vector machine learning with feature selection to discriminate active TB from healthy 
states. Our aim was to identify the fewest transcripts that may be used as a diagnostic biomarker for 
active TB. We used support vector machines (SVMs) to derive discriminating models in the transcrip-
tomic data from patients with and without active TB. This approach allowed us to calculate a weighting 
for each dimension of  the data, relative to its influence in the classification model, and thereby pro-
vided an approach to selecting the discriminating features in genome-wide data. We trained the SVM 
model on multiple random samples of  half  the transcriptomes from the AdjuVIT cohort of  active TB 
and postrecovery cases and ranked all the genes in order of  average SVM weightings (Figure 2A). The 
relative expression of  the highest ranked transcripts was generally higher in active TB compared with 
postrecovery cases (Figure 2B). We tested a cumulative number of  genes in rank order of  their aver-
age weightings for their ability to discriminate between active TB and postrecovery cases using data 
from half  the samples to train the model, and the remaining half  of  the data to test the classification 
Table 1. AdjuVIT cohort
Patient characteristic Active TB (n = 46) Postrecovery (n = 31)
Median age, years (IQR) 30.8 (24.0–37.3) 33.8 (26.7–39.5)
Male, n (%) 38 (83) 28 (90)
Ethnicity, n (%)
Black/Black African 13 (28) 8 (26)
South Asian 22 (48) 14 (45)
East Asian 4 (9) 1 (3)
European/American 7 (15) 8 (26)
Median serum 25(OH) vit D (nM) (IQR) 14 (0–22) 17 (11–33)
Sputum AFB load,  
n (%)
Scanty or 1+ 28 (61) 12 (39)
2+ or 3+ 18 (39) 19 (61)
Cavitation on chest radiograph, n (%) 28 (61) 17 (55)
Median TB treatment, days (IQR) 2 (0–4) N/A
AFB, acid-fast bacilli; IQR, interquartile range; N/A, not available; TB, tuberculosis; vit, vitamin.
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accuracy. In order to mitigate against sampling error, we performed 100 random train/test sequences 
to give average receiver operating characteristic (ROC) area under the curve (AUC) scores (Figure 2C). 
Remarkably, this analysis showed that the highest ranked transcript alone consistently achieved ROC 
AUC scores of  greater than 0.95. This transcript represented expression of  the IFN-inducible gene for 
basic leucine zipper transcription factor 2 (BATF2), which was consistently the most highly ranked fea-
ture of  the data in all the SVM models derived from multiple subsamples (Figure 2A).
BATF2 discriminates active TB from healthy states in multiple study cohorts. Having identified peripheral blood 
BATF2 transcript levels as a biomarker for active TB in the AdjuVIT cohort, we sought to test its ability to 
discriminate active TB from healthy states in multiple independent cohorts. BATF2 expression in patients with 
active TB was significantly higher than that of  healthy volunteers (Berry cohort) (10) and patients with LTBI 
(Bloom and Kaforou cohorts) (11, 15), irrespective of  HIV status, representing data from 402 patients in total 
(Figure 3A). Among HIV-negative patients in these studies, peripheral blood BATF2 expression discriminated 
between active TB and the various healthy cases described in each cohort with ROC AUC scores of  0.93 
to 0.99 (Figure 3B). BATF2 levels discriminated less well between active TB and LTBI cases amongst HIV-
infected patients in the Kaforou cohort (ROC AUC of 0.84). In this cohort, high BATF2 expression in patients 
with active TB was not significantly affected by HIV coinfection, but LTBI cases with HIV coinfection had 
significantly higher BATF2 levels than HIV-negative cases (Figure 3A), partially confounding accurate dis-
crimination between active and latent TB in HIV-infected patients by this measurement. An SVM model 
trained using genome-wide data from the AdjuVIT trial to discriminate active TB and postrecovery cases also 
achieved a ROC AUC of 0.85 for classification of  active and latent TB among HIV-infected patients from the 
Kaforou cohort (Figure 3C). This analysis suggests that in the context of  HIV-1 infection, inclusion of  addi-
tional parameters, even up to a genome-wide level, may not achieve substantially better classification accuracy 
Figure 1. Blood transcriptional signatures associated with active tuberculosis 
(TB). (A) Statistically significant (P < 0.05 by Mann Whitney U test with false 
discovery rate of < 5%) greater than 2-fold differences in transcript abundance in 
genome-wide blood transcriptional profiles of patients with active TB compared 
with postrecovery samples in the AdjuVIT cohort. (B) Gene ontology analysis of 
the genes in A that were expressed at higher levels in AdjuVIT active TB samples 
than in the postrecovery samples. (C) Comparison of significant blood gene 
expression differences in active TB and different healthy states from 3 different 
studies: TB after recovery (AdjuVIT), healthy volunteers (Berry), or people with 
latent TB (Bloom).
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than BATF2 alone, although the use of  alternative kernel functions in the 
SVM model that may improve classification accuracy were not evalu-
ated in the present study (20). Of note, the original description of  the 
Kaforou cohort identified a 27-gene signature that discriminated active 
TB and LTBI in HIV-infected subjects with a ROC AUC of 0.97 (15).
Two other reports have recently proposed the application of  a 
4-gene transcriptional signature comprising GBP1, ID3, P2RY14, and 
IFITM3 (17), and a separate 3-gene transcriptional signature compris-
ing GBP5, DUSP3, and KLF2 (18), as the basis of  potential diagnostic 
tests for active TB. In order to compare their performance with that of  
BATF2 alone, we trained SVM models based on each signature using the 
AdjuVIT active TB and postrecovery samples and tested their classifica-
tion accuracy in the Berry, Bloom, and Kaforou datasets (Table 2). The ROC AUC scores for each signature 
ranged from 0.91 to 0.99 in HIV-negative cases, and was 0.88 in HIV-positive cases. The same HIV-positive 
cases in the original reports of  these alternative gene signatures achieved a ROC AUC of 0.84 using random 
forest models with GBP1, ID3, P2RY14, and IFITM3 (17), and a ROC AUC 0.89 using the difference of  
means of  GBP5, DUSP3, and KLF2 (18). Therefore, we concluded that these 2 alternative multiparameter 
transcriptional signatures were also partially confounded by HIV infection and achieved only modestly better 
performance than BATF2 used as a single biomarker.
Figure 2. Transcriptomic classification of active tuberculosis (TB) and healthy 
cases using support vector machines (SVMs) to identify most discriminat-
ing features. (A) Rank order of weightings for each gene in the SVM training 
model in patients with active TB or after recovery in the AdjuVIT cohort. (B) 
Relative expression of top 10 SVM-ranked genes. (C) Receiver operating char-
acteristic (ROC) area under the curve (AUC) scores of SVM classification of TB 
at diagnosis vs. postrecovery using a cumulative number of genes in rank order 
of weightings. In A and C, data points show the mean with 95% confidence 
intervals of SVM results obtained from 100 iterations in which the dataset was 
randomly split into equal training and test sets.
Figure 3. Classification of active tuberculosis (TB) 
and healthy cases using blood BATF2 transcript 
expression levels. (A) Relative BATF2 gene expres-
sion in blood samples from separate HIV-negative 
and HIV-positive patient cohorts comparing active 
TB with either postrecovery patients (AdjuVIT), 
LTBI (Bloom and Kaforou), or healthy volunteers 
(Berry). Box and whisker plots represent median, 
interquartile, and full range of data points. 
Number of data points in each group is shown in 
parentheses below each plot. *P < 0.0001 (Mann-
Whitney U test). (B) Receiver operating character-
istic (ROC) analyses for discrimination of active 
TB in each of these cohorts using blood levels 
of BATF2 expression only. (C) ROC performance 
of SVM discrimination of active TB from LTBI in 
HIV-positive patients using genome-wide blood 
transcriptional profiles after training on patients 
with active TB and after recovery. In B and C, ROC 
AUCs are shown in parentheses for each cohort.
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The likelihood of  any test giving a true 
result (predictive value) is a function of  the 
pretest probability of  the diagnosis combined 
with the false-positive and false-negative error 
rates. Bayes’ theorem of  conditional prob-
ability is widely used to estimate the positive 
predictive value (PPV) and negative predictive 
value (NPV) of  a test (21). In the different 
study cohorts described above, we used this 
calculation to evaluate the PPV and NPV of  
blood BATF2 transcript levels for identifying 
active TB cases from different healthy states 
for pretest probabilities of  active TB ranging 
from 1% to 50% in order to reflect contexts encompassing low and high incidence of  active TB (Figure 4A). 
At the optimal threshold of  BATF2 transcript levels, defined by the ROC curve Youden index (22), the PPV 
depended strongly on the assumed pretest probability. Across the full range of  pretest probabilities of  1% 
to 50%, the NPV ranged from 85% to 100% in HIV-negative cases and 76% to 100% in HIV-positive cases. 
Restricting the analysis to pretest probabilities of  1% to 10% generated NPVs of  97% to 100%, irrespective 
of  HIV status. Different BATF2 threshold levels could be used to achieve optimal PPV or NPV depending 
on the pretest probabilities (Figure 4B).
SVM classification of  active TB by comparison with other febrile illnesses. Elevated blood BATF2 expression 
in HIV-infected patients with LTBI suggested that increased levels of  BATF2 may not be specific to active 
TB. Therefore, we compared BATF2 expression levels in the blood transcriptomes of  the AdjuVIT cohort 
active TB cases to those of  patients presenting to hospital with febrile illnesses (Fever cohort), represent-
ing a diverse spectrum of  non-TB infectious diseases (Table 3). BATF2 levels among Fever cohort samples 
showed a wide range that overlapped with those of  active TB cases (Figure 5A). Therefore, we inferred 
that higher levels of  BATF2 may reflect nonspecific host responses to infection, much like the acute-phase 
reactant, serum C-reactive protein (CRP) that is widely used as a biomarker for infection and was also 
Figure 4. Positive and negative predictive value 
of blood BATF2 transcript levels to discriminate 
active tuberculosis (TB) from healthy states in 
multiple cohorts. The positive predictive value 
(PPVTB) and negative predictive value (NPVTB) to 
discriminate active TB cases from different healthy 
states is shown for each study cohort for pretest 
probabilities of active TB ranging from 1% to 50% 
using the optimal BATF2 levels determined by the 
Youden index of receiver operating characteristic 
curves in Figure 3 (A), and for a range of blood 
BATF2 threshold levels in which the dotted lines 
represent the BATF2 threshold levels derived from 
the Youden index (B).
Table 2. Receiver operating characteristic AUC comparison of different genes to discriminate active tuberculosis (TB) from healthy states
Cohort name Berry Bloom Kaforou
Groups
Active TB Active TB Active TB Active TB
HV LTBI LTBI LTBI
HIV status Negative Negative Negative Positive
Classification genes 
and method
BATF2 0.96 0.99 0.93 0.84
GBP1, ID3, P2RY14, IFITM3 (using SVM)A 0.91 0.96 0.95 0.88
GBP5, DUSP3, KLF2 (using SVM) 0.95 0.99 0.96 0.88
ASupport vector machine (SVM) models were trained on active TB and postrecovery cases from the AdjuVIT cohort. HV, healthy volunteer;  
LTBI, latent TB infection.
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not significantly different between the 2 groups (Figure 5B). BATF2 
and CRP levels among these patients showed a relatively poor correla-
tion coefficient, suggesting that the 2 parameters were not coregulated 
(Figure 5C). As expected, neither CRP nor BATF2 levels in peripheral 
blood were able to discriminate between active TB and Fever cohort 
samples (Figure 5D).
The alternative 4-gene and 3-gene transcriptional signatures for 
active TB (Table 2) were also reported to show good specificity 
for TB compared with other diseases (17, 18). Using SVM mod-
els trained on half  the AdjuVIT active TB and Fever cohort cases 
and tested on the second half  of  data blinded to the training, we 
showed that each of  these alternative signatures performed substantially better than BATF2 in discrimi-
nating between active TB and other infectious diseases in the Fever cohort, achieving ROC AUCs of  
0.82 to 0.83 (Figure 6A). Similar results were achieved with GBP1, ID3, P2RY14, and IFITM3 using 
random forest models that were utilized in the original report of  this signature (17) (Figure 6B). Inter-
estingly, the difference of  means of  GBP5, DUSP3, and KLF2 advocated in the original report of  this 
signature (18) only achieved a ROC AUC of  0.69 (Figure 6B). Despite performing better than BATF2 
for discriminating between active TB and Fever cases, these ROC AUCs were significantly lower than 
those achieved by these signatures in comparing active TB with healthy states.
Therefore, we sought to further improve the classification accuracy by identifying novel peripheral 
blood transcripts that best differentiate active TB from other infections represented in the Fever cohort. We 
used half  the combined AdjuVIT active TB and Fever cohort transcriptional data sets for SVM training on 
multiple random subsamples to identify their rank order of  average weightings for discriminating active 
TB from Fever cases (Figure 7A). Then we tested a cumulative 
number of  genes in rank order of  their weightings for their abil-
ity to discriminate between active TB and Fever cohort cases for 
their classification accuracy. We carried out 100 random train/
test sequences in each case using the other half  of  the data, and 
then calculated average ROC AUC scores. AUC scores increased 
from approximately 0.9 using the top-ranked gene alone, to 0.99 
using the top 4 genes together, with no significant further gains by 
inclusion of  additional genes (Figure 7B). Each of  the 4 genes in 
this discriminating signature showed significantly different blood 
transcript levels in active TB compared with Fever cohort samples 
(Figure 8A). CD177 and haptoglobin (HP) were expressed at high-
er levels in the Fever cohort samples, whereas immunoglobulin 
Figure 5. BATF2 and C-reactive protein classification of active tuberculosis 
(TB) and other Fever cohort cases. (A) Relative BATF2 gene expression and 
(B) serum C-reactive protein (CRP) levels in blood samples from patients 
with active TB (n = 46) in the AdjuVIT cohort compared with patients with a 
spectrum of other infectious diseases presenting to hospital with fever (n = 
70). Box and whisker plots represent median, interquartile, and full range of 
data points. (C) Scatter plot of blood BATF2 and serum CRP in patients with 
active TB (AdjuVIT cohort). (D) Receiver operating characteristic (ROC) analy-
ses for discrimination of active TB from other Fever cases using either blood 
levels of BATF2 gene expression or serum CRP only. ROC AUCs are shown in 
parentheses for each cohort.
Figure 6. Transcriptomic classification of active tuberculosis (TB) and other Fever cohort cases. Receiver 
operating characteristic (ROC) analyses for discrimination of active TB from other Fever cases using expres-
sion data for (A) GBP1, ID3, P2RY14, and IFITM3 or (B) GBP5, DUSP3, and KLF2 by training SVM or random 
forest models as indicated on half of the AdjuVIT active TB and Fever cohort samples and testing the model 
performance on the second half, or by using the difference of means of (GBP5 + DUSP3) – KLF2 as described 
by Sweeney et al. (18). ROC AUCs are shown in parentheses for each analysis.
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J region (IGJ) and galectin 10 (CLC) were expressed at 
higher levels in the active TB samples.
In order to validate their potential to discriminate 
between active TB and Fever cases, an SVM model was 
trained with transcriptional data for these 4 genes using the 
entire first half  of AdjuVIT active TB and Fever cohort 
cases, and tested on the entire second half  of the cases 
that had not been included in the identification of these 
genes (Figure 8B). The 4-gene signature provided almost 
perfect classification of the test samples with a ROC AUC 
of 0.99. For comparison, we also tested the top-ranked 
gene, CD177, which discriminated between active TB and 
Fever cohort test cases with a ROC AUC of 0.94. CD177 
is a cell surface glycoprotein expressed by subpopulations 
of neutrophils (23–25), but the correlation coefficient with 
neutrophil counts in the AdjuVIT active TB and Fever 
cohort samples was only 0.23 (Figure 8C). This suggested 
that increased levels of CD177 in the Fever cohort samples 
are not simply a surrogate for increased frequency of cir-
culating neutrophils, but may represent transcriptional 
upregulation of CD177 in these cases compared with active 
TB. We also noted that HP is recognized as an acute-phase 
reactant and tested the correlation of HP transcript levels 
with levels of circulating CRP, but found very modest cor-
relation between these 2 parameters as well (Figure 8D). 
These data suggest that increased levels of HP transcripts 
in non-TB infectious diseases cases reflect context-specific 
transcriptional upregulation rather than a surrogate for 
nonspecific acute-phase responses.
There were significant differences in ethnicity, age, 
and sex between the AdjuVIT active TB and Fever 
cohort patients (Supplemental Table 2). However, the 
different patterns of  gene expression that discriminate 
between the 2 cohorts were evident in all ethnic groups and not confounded by age or sex (Figure 9). 
Moreover, training the 4-gene-signature SVM model using data from each ethnic group allowed accu-
rate classification of  cases in all other ethnic groups (Figure 10, A–C). In addition, significant differ-
ences in age and blood neutrophil or lymphocyte counts (Supplemental Table 2) discriminated poorly 
between active TB and Fever cases (Figure 10, D–F).
Derivation of  a single risk score for test cases. Binary classification of  cases by SVM does not provide 
a case-by-case estimate of  confidence in the accuracy of  the classification. In order to achieve this, we 
fitted the distance of  each test case from the SVM separating hyperplane to a sigmoid logistic regres-
sion function to give a probability estimate between 0 and 1 (26), thereby generating a risk score for 
each of  the test cases based on the SVM model derived from our 4-gene signature (Figure 11A). Given 
that BATF2 can discriminate between active TB and healthy cases, and that an additional 4 genes can 
discriminate active TB from a wide range of  other infectious diseases presenting with fever, we sought 
to combine the expression levels of  BATF2 with CD177, HP, IGJ, and CLC in a single SVM model to 
discriminate active TB from postrecovery cases in the AdjuVIT cohort, and from other diseases in the 
Fever cohort. The SVM model was trained using the 5-gene signature on half  of  the AdjuVIT active TB 
cases in 1 group and half  of  the AdjuVIT postrecovery TB cases pooled with half  of  the Fever cohort 
cases in a second group. This model was then used to classify the remaining second half  of  the cases 
in all 3 groups, providing a single risk score of  active TB for each case and giving a ROC AUC of  0.95 
(Figure 11, B and C).
Bayes’ theorem was also used to calculate the PPV and NPV of  using CD177 alone or the combi-
nation of  CD177, HP, IGJ, and CLC to discriminate active TB from other infections, and the combina-
Table 3. Fever cohort case mix
System n (%) Syndrome n (%)
Urinary Tract 23 (32.9)
Urinary tract infection 10 (14.3)
Pyelonephritis 12 (17.1)
Epididymo-orchitis 1 (1.4)
Respiratory 17 (24.3)
Pneumonia 10 (14.3)
Pharyngitis 5 (7.1)
Infective exacerbation of COPD 1 (1.4)
LRTI without CXR changes 1 (1.4)
Systemic 8 (11.4)
Malaria: non-falciparum 2 (2.9)
Unspecified viral infection 2 (2.9)
Neutropenic sepsis 1 (1.4)
Septicemia 1 (1.4)
Unspecified 1 (1.4)
Varicella 1 (1.4)
Gastrointestinal 6 (8.6)
Diverticulitis 2 (2.9)
Gastroenteritis 2 (2.9)
Appendicitis 1 (1.4)
Intra-abdominal collection 1 (1.4)
Skin and Soft Tissue 5 (7.1)
Cellulitis 2 (2.9)
Surgical wound infection 2 (2.9)
Abscess 1 (1.4)
Hepatobiliary 4 (5.7)
Cholangitis 2 (2.9)
Cholecystitis 1 (1.4)
Liver abscess 1 (1.4)
Other 4 (5.7)
Unknown etiology 3 (4.3)
Rheumatological 1 (1.4)
Gynecological 1 (1.4) Pelvic collection 1 (1.4)
Cardiovascular 1 (1.4) Infective endocarditis 1 (1.4)
Dental and Perioral 1 (1.4) Dental abscess 1 (1.4)
COPD, chronic obstructive pulmonary disease; LRTI, lower respiratory tract infection; 
CXR, chest x-ray.
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tion of  BATF2, CD177, HP, IGJ, and CLC to discriminate active TB from 
either healthy states or other infections for a range of  pretest probabilities, 
revealing the optimal PPV or NPV that can be achieved (Figure 12). At the 
optimal Youden index threshold, the application of  the potentially novel 
4-gene signature to discriminate active TB from other infectious diseases, 
generated wide-ranging PPVs dependent on the pretest probability but an NPV of  100%, even assuming 
the highest pretest probability for TB of  50%.
Blood transcriptional signatures for active TB are independent of  the site of  disease. All the active TB cases 
in the AdjuVIT, Berry, and Bloom cohorts were of  pulmonary TB. Novel diagnostic biomarkers for TB 
are particularly needed for extrapulmonary TB in which existing microbiological diagnostics have the 
lowest sensitivity. Therefore, we obtained new blood transcriptomic data from additional independent 
cases to evaluate the utility of  BATF2 and the 4-gene TB-specific transcriptional signature described 
above by comparison of  healthy individuals and those with LTBI, active pulmonary or extrapulmo-
nary TB, and non-TB respiratory tract infection before any antibiotic treatment. By comparison with 
healthy volunteers, blood BATF2 transcript levels were significantly higher in both pulmonary and 
extrapulmonary TB cases (Figure 13A). Elevated BATF2 classified cases of  pulmonary TB with a ROC 
AUC of  0.98 and extrapulmonary cases with a ROC AUC of  0.96 (Figure 13B). Finally, an SVM 
model trained with data from AdjuVIT active TB and all Fever cohort cases using the 4-gene TB-spe-
cific signature of  CD177, HP, 
IGJ, and CLC, discriminated 
between new pulmonary or 
extrapulmonary TB cases 
and non-TB febrile pneumo-
nia with ROC AUCs of  0.99 
and 1, respectively (Figure 
13, C and D). Therefore, we 
concluded that BATF2 and 
the 4-gene TB blood tran-
scriptional signatures per-
formed equally well in clas-
sification of  both pulmonary 
and extrapulmonary TB.
Figure 7. Transcriptomic classification of active tuberculosis (TB) and other infec-
tions represented by the Fever cohort cases using support vector machines (SVMs) 
to identify most discriminating features. (A) Rank order of weightings for each gene 
in the SVM training model of patients with active TB or other Fever. (B) Receiver 
operating characteristic (ROC) AUCs of SVM classification of active TB or other Fever 
using a cumulative number of genes in rank order of weightings. Data points show 
mean with 95% confidence intervals obtained from 100 iterations in which one half 
of the dataset was randomly separated into training and test sets for the SVM.
Figure 8. Transcriptomic classification of active tuberculosis (TB) 
and other Fever cohort cases with 4 genes. (A) Relative expression of 
each of the genes indicated in peripheral blood of patients with active 
TB (AdjuVIT, n = 46) and other Fever (n = 70) cohorts. Box and whisker 
plots represent median, interquartile, and full range of data points, *P 
< 0.0001 (Mann-Whitney U test). (B) Receiver operating characteristic 
(ROC) analyses of support vector machine (SVM) discrimination of active 
TB (AdjuVIT) from other Fever patients using expression levels of the 
CD177 gene alone or all 4 of the genes indicated, by training half of the 
data used to derive rank order of SVM weightings and then testing on 
the second half of the data. ROC AUCs are shown in parentheses for 
each test. (C) Scatter plots of blood CD177 and blood neutrophil counts, 
and (D) blood haptoglobin (HP) transcripts and serum C-reactive protein 
(CRP) concentrations in AdjuVIT active TB and Fever cohorts. In C and D, 
dotted line represents regression line giving R2 value indicated.
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Discussion
We have identified and validated elevated 
BATF2 levels as a discriminating blood 
transcriptional biomarker for active TB 
compared with healthy uninfected indi-
viduals, people with LTBI, and people 
with long-term recovery from active TB. 
Our assessment of  226 cases of  TB and 
176 healthy individuals among HIV-sero-
negative adults across 4 separate study 
cohorts with diverse ethnic backgrounds 
consistently gave ROC AUCs of  0.93 to 
0.99. The performance of  BATF2 as single 
transcriptional biomarker in these cohorts 
was comparable to the performance of  
other recently reported transcriptional 
signatures of  active TB based on 4 genes 
(GBP1, ID3, P2RY14, and IFITM3) (17) or 
3 genes (GBP5, DUSP3, and KLF2) (18).
BATF2 belongs to the activator pro-
tein 1 (AP-1) transcription factor family, 
with IFN-inducible expression in mono-
nuclear phagocytic cells, and is upregu-
lated by innate immune stimulation with 
lipopolysaccharide or Mtb. BATF2 inter-
acts with IFN regulatory factor 1 (IRF1) 
to mediate downstream proinflammatory 
responses, some of  which are also recog-
nized as components of  the host response 
to Mtb (27, 28). Given that systemic IFN activity is widely recognized in active TB (10), increased BATF2 
expression is most likely due to IFN responses rather than direct Mtb stimulation of  circulating blood cells. 
Discrimination of  active TB and LTBI in HIV-infected individuals using blood BATF2 transcript levels 
achieved a ROC AUC level of  0.84. BATF2 transcript levels in HIV-infected and uninfected active TB cases 
were not significantly different, and the variance of  BATF2 in all study groups was broadly similar. Instead, 
reduced classification accuracy was due to higher levels of  BATF2 in HIV-infected LTBI cases, which we 
speculate reflects chronic HIV-associated IFN activity (29). Longitudinal comparison of  BATF2 transcript 
levels in HIV-1–infected patients before and after initiation of  HIV treatment and completion of  TB treat-
ment may offer the opportunity to dissect the independent effects of  HIV and TB infection on BATF2 levels.
Our current data suggest that in HIV-infected cases, BATF2 transcript levels may be expected to offer 
better negative predictive value as a biomarker for active TB than positive predictive value. Interestingly, 
discrimination of  active TB and LTBI cases in HIV-infected people using genome-wide transcriptional 
data did not yield a better ROC AUC than BATF2 by itself, suggesting that even combinations of  other 
transcripts will not afford better classification accuracy using SVM. This hypothesis is partially borne out 
by the assessment of  the alternative concise transcriptional signatures described above which achieved a 
Figure 9. Comparison of selected biomarkers 
in subgroups of active tuberculosis (TB) and 
Fever cohort cases. Relative expression of 
each of the genes indicated in peripheral blood 
of patients of specific ethnicity, males, or age 
less than 40 years, within AdjuVIT active TB 
and other Fever cohorts. Box and whisker plots 
represent median, interquartile, and full range 
of data points. Number of cases in each group 
is shown in parentheses.
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ROC AUC of  0.88 in the same analysis, but more 
complex transcriptional signatures of  27 genes were 
reported to achieve a ROC AUC of  0.97 to discrim-
inate between active TB and LTBI in HIV-positive 
adults (15). Even in the context of  HIV infection, at 
the optimal balance between sensitivity and speci-
ficity in ROC curve analysis, the negative predictive 
value of  BATF2 as a biomarker for active TB only 
falls below 95% if  the pretest probability of  active TB is greater than 15%. In settings with high pretest prob-
ability (up to 50%), alternative threshold BATF2 levels can yield greater than 95% negative predictive value 
while retaining a positive predictive value of  80%. These provide better risk stratification of  active TB in 
HIV-infected patients than any other single biomarker described to date.
Consistent with our observations in HIV-1 infection, we found that elevated BATF2 levels were not 
specific to active TB, but were also variably elevated in HIV-negative patients presenting to hospital with 
diverse infectious diseases. Like other nonspecific markers of  inflammation such as serum CRP, they did not 
discriminate TB from other infections. Instead we identified and validated a separate transcriptional signa-
ture comprising 4 genes that can be summarized into a single probability score to discriminate these classes 
with ROC AUCs of  0.96 to 1, in analyses including 84 patients with active TB and 90 patients with other 
infections. This transcriptional signature provided much better discrimination of  TB from the spectrum of  
infectious diseases included than other recently reported blood gene signatures (17, 18). In addition, we 
showed that the transcriptional signature was independent of  multiple potential confounders such as sex, 
age, and ethnicity for which there were significant differences between the 2 groups. Within this 4-gene sig-
nature, transcript levels for a neutrophil G protein–linked surface glycoprotein (CD177), and the acute-phase 
hemoglobin scavenging plasma protein (HP), were elevated in non-TB infection cases. By contrast, active 
TB cases showed elevated transcript levels for IGJ and the glycan-binding protein, galectin 10 (CLC). Given 
the association between CD177 and neutrophils, and that blood neutrophil counts in active TB were signifi-
cantly lower than the non-TB infection group, lower CD177 transcript levels in active TB might also have 
been expected, but the correlation coefficient between these variables was relatively low and CD177 by itself  
provided much better discrimination between the classes than neutrophil counts. Hence, we conclude that 
CD177 transcripts were not simply a surrogate for neutrophil counts but also reflected differential transcrip-
tional regulation between the 2 classes. Likewise, HP levels showed only very modest correlation with the 
archetypal acute-phase reactant, CRP, also suggesting context-specific transcriptional upregulation rather 
than a component of  nonspecific acute-phase responses. The mechanistic model for increased transcript 
levels of  IGJ and CLC in active TB is unclear, but we note that galectin 10 has previously been evaluated as 
a biomarker for eosinophilic lung inflammation (30). This raises the possibility that the inclusion of  galec-
tin 10 in this transcriptional signature may be confounded by overrepresentation of  pulmonary diseases in 
active TB cases used in the SVM training cohort. However the 4-gene signature performed equally well in 
discriminating extrapulmonary TB from non-TB pneumonia cases in independent datasets, thereby increas-
ing our confidence that the discriminating transcriptional signatures were not confounded by the site of  
disease, and importantly, may be equally valid in pulmonary and extrapulmonary TB. Further assessment 
of  these transcriptional signatures is needed in different clinical contexts to evaluate the impact of  different 
Figure 10. Classification of active tuberculosis (TB) 
and Fever cohort cases using a 4-gene transcriptional 
signature in specific ethnic groups, blood cell counts, 
and age. (A–C) Receiver operating characteristic (ROC) 
analyses of support vector machine discrimination of 
active TB (AdjuVIT) from other Fever patients using 
expression levels of CD177, HP, IGJ, and CLC in each of the 
ethnicities indicated, by training on (A) European and 
American (EURAM) patients, (B) Black African (BLAF) 
patients, and (C) South Asian (SASIA) patients in each 
cohort. (D–F) ROC analyses for discrimination of active 
TB from other Fever cases using either blood neutrophil 
counts (D), lymphocyte counts (E), or age (F). ROC AUCs 
are shown in parentheses for each test.
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repertoires of  non-TB diagnoses, partially treated infections, and 
HIV coinfection, on their performance as diagnostic biomarkers. 
In this respect the greatest challenges are likely to arise in individu-
als with sarcoidosis, which shares the hallmark of  granulomatous 
inflammation, and in advanced HIV infection, where coinfection 
with multiple opportunistic pathogens is common. We speculate that 
it is unlikely that a single concise diagnostic blood transcriptional 
signature will provide adequate specificity for active TB compared 
with all possible differential diagnoses, but that a repertoire of  diagnostic signatures will emerge to support 
context-specific clinical decisions. Additional studies are also required to test whether the same gene prod-
ucts may function as biomarkers in protein assays, which remain more economically viable than transcrip-
tional assays and have better opportunities for development as point-of-care tests.
The present study focused on symptomatic patients. Importantly, identification of  active TB in asymp-
tomatic patients also represents a substantial burden for clinical TB services among patients with chest 
radiographic changes compatible 
with TB, contacts of  patients with 
active TB, and in other systematic 
programs for active case finding, 
including screening of  migrants, 
health care workers, and HIV-1–
infected patients before starting 
antiretroviral therapy (31, 32). In 
these settings, preclinical diagno-
sis of  progressive TB is likely to 
have a significant beneficial effect 
on reducing onward transmission 
of  infection. Further longitudinal 
cohort studies are required to test 
the performance of  these biomark-
ers in asymptomatic patients. Of  
note, in one such study from South 
Figure 11. Derivation of a single risk score from multiparametric classifica-
tion of active tuberculosis (TB). (A) Transformation of the distance of each 
of the test cases of active TB (AdjuVIT cohort, n = 23) and other infectious 
diseases (Fever cohort, n = 35) from the SVM separating hyperplane derived 
from the training half using CD177/HP/IGJ/CLC transcript data, to give a 
case-by-case probability of TB. (B) Receiver operating characteristic (ROC) 
analyses of support vector machine (SVM) discrimination of AdjuVIT active 
TB from pooled AdjuVIT after recovery and Fever cohort patients using 
expression levels of the 5 genes indicated by training half of the data and 
then testing on the second half of the data independently of the original 
derivation of the gene signature (Figure 7). ROC AUCs are shown in paren-
theses for each test. (C) Transformation of the distance of each test case in 
B from the SVM separating hyperplane derived from the training half, using 
all 5 genes indicated, to give a case-by-case probability of TB.
Figure 12. Positive and negative predictive value of selected blood tran-
script levels to discriminate active tuberculosis (TB) from other infectious 
diseases presenting with fever. The positive predictive value (PPVTB) and 
negative predictive value (NPVTB) to discriminate active TB cases from 
other infectious diseases with fever is shown for pretest probabilities of 
active TB ranging from 1% to 50% using the optimal levels of CD177 alone, 
or the 4- and 5-gene signatures indicated, determined by the Youden index 
of receiver operating characteristic curves in Figures 8B and 11B (A), and for 
a range of biomarker thresholds, in which the dotted lines represent the 
thresholds derived from the Youden index (B).
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Africa and The Gambia, BATF2 was included in a 16-gene 
blood transcriptional signature with 66% sensitivity and 
80% specificity for predicting diagnosis of  active TB among 
asymptomatic subjects within the following 12 months 
(33). Test performance might be expected to improve sig-
nificantly at shorter intervals before the onset of  symptoms.
The analysis of  the transcriptional biomarkers identi-
fied in the present study suggests that their performance in 
diagnostic tests meets WHO targets (7). We conclude that 
it may be possible to use a single biomarker (BATF2) to rule 
out active TB, but multiplex technology will be required to discriminate TB from other diseases. The devel-
opment pathway to translate these biomarkers to novel diagnostics will require standardization of  measure-
ments and thresholds. In addition, the design of  future studies to provide extended validation and clinical 
trials to test their impact should incorporate consideration of  the pretest probabilities for TB, which may 
have substantial impact on the positive and negative predictive value of  each test. In general, our analyses 
show that the NPV of  the transcriptional biomarkers identified was better than the PPV, suggesting that 
application of  these tests may have greatest impact as a triage test to rule out active TB or otherwise identify 
patients for further investigation. Additional risk stratification to modulate the pretest probabilities or use 
of  alternative threshold values in different clinical contexts may be necessary to realize maximum benefi-
cial impact on clinical decision support. These transcriptional biomarkers offer exciting opportunities for 
the development of  new rapid diagnostics in TB to overcome the current limitations in microbiological 
diagnosis, particularly in extrapulmonary disease or in active case finding, and in order to avoid unneces-
sary investigations, unnecessary treatment, and delays in initiation of  treatment.
Methods
Study approval. Blood sampling for transcriptomic analyses was approved by UK National Research Eth-
ics services (reference numbers: 09/H0701/103, 14/EE/0097, 06/Q0605/83; 12/LO/0504). All subjects 
provided written informed consent.
Study participants. Blood samples were collected in Tempus or PAXgene tubes from healthy volunteers, 
patients with smear-positive pulmonary TB recruited to the AdjuVIT trial (19) at diagnosis and more than 
2 years after recovery, patients with pulmonary or extrapulmonary active TB and latent TB infection in the 
North Central London TB service, and from patients presenting to University College London Hospital 
emergency department with body temperatures greater than 38°C or a clinical diagnosis of  pneumonia 
(based on body temperature greater than 38°C and chest radiographic changes) before receipt of  antimicro-
bial treatment (Supplemental File 1).
Peripheral blood transcriptional profiling. RNA was extracted using the Tempus Spin RNA Isolation kit 
(Applied Biosystems) or PAXgene 96 Blood RNA Kit (PreAnalytiX). Genomic DNA was removed with the 
TURBO DNA-free kit (Ambion). RNeasy MinElute Cleanup kit (QIAGEN) was used to concentrate the 
RNA before globin mRNA depletion with GLOBINclear kit (Ambion) and RNA quality control was assessed 
Figure 13. Pulmonary and extrapulmonary tuberculosis (TB) 
discrimination from healthy cases and non-TB pneumonia. (A) 
Relative BATF2 gene expression in blood samples from a new 
independent cohort of patients with pulmonary TB (PTB, n = 24), 
extrapulmonary TB (EPTB, n = 14), or from healthy volunteers (n 
= 29) and subjects with latent TB infection (LTBI, n = 11). Box and 
whisker plots represent median, interquartile, and full range of 
data points. *P < 0.0001 (Mann-Whitney U test). (B) Receiver 
operating characteristic (ROC) analyses of support vector machine 
(SVM) discrimination of PTB and EPTB from healthy volunteers 
or LTBI cases based on the BATF2 levels in A. (C) ROC analyses 
of SVM discrimination of new PTB and EPTB from cohort of new 
non-TB pneumonia cases after training the SVM model on active 
TB (AdjuVIT) and other Fever cases using relative expression 
levels of CD177/HP/IGJ/CLC. (D) Transformation of the distance of 
each test case in C from the SVM separating hyperplane, using all 
4 genes indicated, to give a case-by-case probability of TB.
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using the Agilent 2100 Bioanalyzer (Agilent Technologies). Fluorophore-labeled cRNA was then generated 
using the Low Input Quick Amp labeling kit, and hybridized to SurePrint G3 Human Gene Expression v3 8 × 
60K or Human Gene Expression v2 4 × 44K whole-genome microarrays (Agilent Technologies). Array imag-
es were acquired with Agilent’s dual-laser microarray scanner G2565BA and analyzed with Agilent Feature 
Extraction software (v9.5.1). Log2-transformed median Cy3 and Cy5 signal intensities were normalized using 
LOESS local linear regression against the mean signal of  all the samples using the R package agilp (34, 35).
Data analysis. Analysis of  all microarray data was conducted on log2-transformed data (35) and restrict-
ed to gene symbol–annotated probes expressed above background negative-control levels in at least 1 sam-
ple. Significant gene expression differences between datasets were identified using Mann-Whitney U tests 
for nonparametric data in MultiExperiment Viewer v4.9 (http://www.tm4.org/mev.html) with a false dis-
covery rate of  0.05 and a filter for greater than 2-fold differences in median normalized expression values. 
Gene ontology and pathway analyses were performed in innateDB (36). Network graphics of  gene and 
pathway association were generated using Gephi (http://gephi.github.io/). All microarray data used in 
this study are available in ArrayExpress (https://www.ebi.ac.uk/arrayexpress/) under the accession num-
bers provided (Supplemental Table 1). SVMs, which learn an optimal hyperplane separating 2 sets of  data 
in high-dimensional space, were used to classify the transcriptome data from different samples (37). The R 
statistical computing platform (v3.0.2) was used to implement the SVM algorithms using the kernlab pack-
age with a linear kernel. The SVM was trained and tested on independent datasets. The package computes 
either a binary classification or a probability score for each sample by fitting a logistic regression model to 
the Euclidean distance of  each case from the hyperplane (26). The package also computes a weighting for 
the importance of  each transcript in determining the overall classification. Classification performance was 
evaluated using ROC curves, with the AUC as a summary statistic. ROC curves were constructed from the 
output of  the SVM using the R package pROC. The optimal cutoff  point in ROC curves was identified by 
that which gives the smallest Youden index calculated from the sum of  sensitivity and specificity – 1. Bayes-
ian conditional probabilities were calculated as previously described (21).
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